- Home
- CNTA vs CORT Comparison
CNTA vs CORT Comparison
Compare CNTA & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTA | CORT |
|---|---|---|
| Founded | 2020 | 1998 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.7B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNTA | CORT |
|---|---|---|
| Price | $25.65 | $46.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | $38.00 | ★ $114.20 |
| AVG Volume (30 Days) | 1.6M | ★ 3.4M |
| Earning Date | 11-05-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.87 |
| Revenue | $15,000,000.00 | ★ $741,172,000.00 |
| Revenue This Year | N/A | $21.70 |
| Revenue Next Year | N/A | $30.13 |
| P/E Ratio | ★ N/A | $52.92 |
| Revenue Growth | ★ 118.88 | 17.92 |
| 52 Week Low | $9.60 | $32.99 |
| 52 Week High | $30.58 | $117.33 |
Technical Indicators
Market Signals| Indicator | CNTA | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 60.26 | 43.71 |
| Support Level | $21.50 | $34.06 |
| Resistance Level | $26.63 | $37.48 |
| Average True Range (ATR) | 1.13 | 1.99 |
| MACD | 0.52 | 2.48 |
| Stochastic Oscillator | 81.48 | 94.15 |
Price Performance
Historical ComparisonAbout CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.